Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
A Randomised, Double-blind, Four-period, Cross-over, Dose Response Trial Investigating the Pharmacodynamics and Pharmacokinetics of Single Doses of Insulin Detemir and NPH Insulin in Subjects With Type 2 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Graz, Germany, 8036
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes
- Subjects treated with insulin for minimum 3 months
- Duration of diabetes for at least 12 months
- Body Mass Index (BMI) below 30 kg/m^2
- HbA1c maximum 10% based on analysis from central laboratory
Exclusion Criteria:
- Current treatment with insulin above 1.2 U/kg/day
- Current treatment with insulin glargine
- Current treatment with drugs known to interfere with glucose metabolism
- Current treatment with oral antidiabetic drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: insulin NPH
|
Each subject will be randomly allocated to two dose administrations out of four possible doses.
Administrated subcutaneously (s.c., under the skin)
|
|
Experimental: insulin detemir
|
Each subject will be randomly allocated to two dose administrations out of four possible doses.
Administrated subcutaneously (s.c., under the skin)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Area under the glucose infusion rate curve
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Terminal half-life
|
|
Area under the curve
|
|
Maximum glucose infusion rate
|
|
Terminal rate constant
|
|
Time to maximum glucose
|
|
Maximum concentration
|
|
Time to maximum concentration
|
|
Insulin clearance
|
|
Mean residence time of insulin
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN304-1538
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.